Sonoma Pharmaceuticals (SNOA)

A central part of Sonoma’s portfolio is based on stabilized hypochlorous acid technology, marketed under brands that include Microcyn and related product families. Hypochlorous acid is used in topical applications because of its antimicrobial and cleansing properties, and Sonoma positions these products for uses such as wound management, minor skin irritations, rashes, and other dermatologic needs. The company’s broader product lineup has included brands such as Celacyn for scar management, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, and SebuDerm, addressing areas such as acne, atopic dermatitis, itching, seborrheic dermatitis, and compromised skin barriers.

Sonoma sells products in the United States and through international distribution relationships in regions including Latin America, Europe, and Asia. Its business model combines direct commercialization in selected markets with partnerships that help extend its reach without requiring a large global sales infrastructure. Revenue is generated from product sales, distribution arrangements, and licensing or collaboration structures tied to its dermatology and wound-care technologies.

The company operates in competitive markets where brand awareness, regulatory classifications, physician adoption, reimbursement, and retail access can influence performance. Sonoma is distinctive for its concentration on topical therapies and skin-care solutions that bridge medical dermatology, wound treatment, and over-the-counter-style applications rather than relying on a single prescription drug franchise.